(13) Innovation at the United States Agency for International Development is primarily supported from siloed disease- and population-specific appropriations accounts, resulting in the limitation of its ability to seek shared value across health sectors or health threats. (14) The United States Agency for International Development is compelled to prioritize support for immediate program needs with imperfect tools at the expense of support for technologies that can improve clinical effectiveness, increase access to care, save costs, and build capacity and ownership by partner countries. 3. Statement of policy It is the policy of the United States that— (1) research and development for new health technologies is essential for the success of the global health programs of the United States Government, by providing for the improved effectiveness, cost-effectiveness, and sustainability of such programs